je.st
news
Allergan may turn sights to Amgen or AbbVie with Teva cash
2015-07-28 18:30:04| Biotech - Topix.net
Allergan Plc says it's “reloaded and ready to move” on further acquisitions after agreeing to sell its generic-drug business for $40.5 billion. The deal with Teva Pharmaceutical Industries Ltd. “gives us a tremendous amount of flexibility to think about transformational M&A as well as continue our pattern of tuck-in acquisitions,” Allergan Chief Executive Officer Brent Saunders said on a conference call today.
Tags: with
turn
cash
sights
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|
|||